Reduced sales of livestock products for Zoetis in Europe

Sales of livestock products decreased 6% operationally for Zoetis in Europe, Africa and the Middle East, according to the latest figures from the company. 

It said this was primarily driven by a decline in the UK associated with one-time impacts in the quarter including a decline in poultry products related to regulatory issues that have been resolved and a decline in swine products linked to reductions in the use of anti-infectives. These overall livestock declines were partially offset by growth of cattle products in emerging markets, it said.

Sales of companion animal products increased 1% operationally, primarily driven by the launch of Apoquel in Germany and the UK, and the sale of parasiticides in France, Italy and emerging markets.

The company announced its first quarter results for 2014, with an increase in revenue of 1%. The company reported revenue of $1.1 billion for the first quarter of 2014. Zoetis

Zoetis is a global animal health company which was a subsidiary of Pfizer. Pfizer spun off its 83% share of the company in 2012. Today, Zoetis products include Stronghold, Dectomax and Draxxin.

Please be considerate of others when commenting. All comments posted are subject to our commenting policy. Comments violating this policy will be removed without notice.